Public Joint-Stock Company "Human Stem Cells Institute" ISKJ.ME Stock
Public Joint-Stock Company "Human Stem Cells Institute" Price Chart
Public Joint-Stock Company "Human Stem Cells Institute" ISKJ.ME Financial and Trading Overview
Contents
- Public Joint-Stock Company "Human Stem Cells Institute" Price Chart
- Public Joint-Stock Company "Human Stem Cells Institute" ISKJ.ME Financial and Trading Overview
- Valuation Measures
- Trading Information
- Financial Highlights
- Profile of Public Joint-Stock Company "Human Stem Cells Institute"
- Q&A For Public Joint-Stock Company "Human Stem Cells Institute" Stock
Public Joint-Stock Company "Human Stem Cells Institute" stock price | 59.54 RUB |
Previous Close | 58.7 RUB |
Open | 59.3 RUB |
Bid | 60.24 RUB x 10000 |
Ask | 60.22 RUB x 70000 |
Day's Range | 59.12 - 61.82 RUB |
52 Week Range | 59.12 - 77.1 RUB |
Volume | 261.91K RUB |
Avg. Volume | 0 RUB |
Market Cap | 4.86B RUB |
Beta (5Y Monthly) | 1.17226 |
PE Ratio (TTM) | 229.00002 |
EPS (TTM) | 0.26 RUB |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | July 11, 2023 |
1y Target Est | N/A |
ISKJ.ME Valuation Measures
Enterprise Value | 5.69B RUB |
Trailing P/E | 229.00002 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.2738824 |
Price/Book (mrq) | 14.247428 |
Enterprise Value/Revenue | 5.007 |
Enterprise Value/EBITDA | 33.014 |
Trading Information
Public Joint-Stock Company "Human Stem Cells Institute" Stock Price History
Beta (5Y Monthly) | 1.17226 |
52-Week Change | 0% |
S&P500 52-Week Change | 20.43% |
52 Week High | 77.1 RUB |
52 Week Low | 59.12 RUB |
50-Day Moving Average | 77.1 RUB |
200-Day Moving Average | 77.1 RUB |
ISKJ.ME Share Statistics
Avg. Volume (3 month) | 0 RUB |
Avg. Daily Volume (10-Days) | 0 RUB |
Shares Outstanding | 81.61M |
Float | 23.56M |
Short Ratio | N/A |
% Held by Insiders | 75.20% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 1 |
Trailing Annual Dividend Yield | 1.70% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 4.05% |
Operating Margin (ttm) | 11.76% |
Gross Margin | 62.15% |
EBITDA Margin | 15.16% |
Management Effectiveness
Return on Assets (ttm) | 4.42% |
Return on Equity (ttm) | 4.47% |
Income Statement
Revenue (ttm) | 1.14B RUB |
Revenue Per Share (ttm) | 13.08 RUB |
Quarterly Revenue Growth (yoy) | -1.099% |
Gross Profit (ttm) | N/A |
EBITDA | 172.44M RUB |
Net Income Avi to Common (ttm) | 46.12M RUB |
Diluted EPS (ttm) | 0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 227.06M RUB |
Total Cash Per Share (mrq) | 2.78 RUB |
Total Debt (mrq) | 831.6M RUB |
Total Debt/Equity (mrq) | 145.83 RUB |
Current Ratio (mrq) | 1.744 |
Book Value Per Share (mrq) | 4.179 |
Cash Flow Statement
Operating Cash Flow (ttm) | 220.3M RUB |
Levered Free Cash Flow (ttm) | -116590128 RUB |
Profile of Public Joint-Stock Company "Human Stem Cells Institute"
Country | Russia |
State | N/A |
City | Moscow |
Address | 18/1 Olimpiysky prospect |
ZIP | 129110 |
Phone | 7 495 646 8076 |
Website | https://hsci.ru |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Public Joint-Stock Company Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.
Q&A For Public Joint-Stock Company "Human Stem Cells Institute" Stock
What is a current ISKJ.ME stock price?
Public Joint-Stock Company "Human Stem Cells Institute" ISKJ.ME stock price today per share is 59.54 RUB.
How to purchase Public Joint-Stock Company "Human Stem Cells Institute" stock?
You can buy ISKJ.ME shares on the MCX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Public Joint-Stock Company "Human Stem Cells Institute"?
The stock symbol or ticker of Public Joint-Stock Company "Human Stem Cells Institute" is ISKJ.ME.
Which industry does the Public Joint-Stock Company "Human Stem Cells Institute" company belong to?
The Public Joint-Stock Company "Human Stem Cells Institute" industry is Biotechnology.
How many shares does Public Joint-Stock Company "Human Stem Cells Institute" have in circulation?
The max supply of Public Joint-Stock Company "Human Stem Cells Institute" shares is 81.61M.
What is Public Joint-Stock Company "Human Stem Cells Institute" Price to Earnings Ratio (PE Ratio)?
Public Joint-Stock Company "Human Stem Cells Institute" PE Ratio is 229.00002000 now.
What was Public Joint-Stock Company "Human Stem Cells Institute" earnings per share over the trailing 12 months (TTM)?
Public Joint-Stock Company "Human Stem Cells Institute" EPS is 0.26 RUB over the trailing 12 months.
Which sector does the Public Joint-Stock Company "Human Stem Cells Institute" company belong to?
The Public Joint-Stock Company "Human Stem Cells Institute" sector is Healthcare.
Stocks Related By Industry
Stocks Related By Marketcap
- Public Joint Stock Company The Taganrog Boiler-Making Works Krasny Kotelshchik KRKOP.ME Stock
- Public Joint Stock Company "TNS energo Rostov-on-Don" RTSB.ME Stock
- Public Joint Stock Company Rosseti South MRKY.ME Stock
- Public Joint Stock Company Saratov Oil Refinery KRKNP.ME Stock
- Public Joint-Stock Energy and Electrification Company Samaraenergo SAGO.ME Stock